26-Mar-2026
TipRanks (Mon, 23-Mar 6:15 AM ET)
Market Chameleon (Mon, 16-Mar 3:53 AM ET)
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
PRNewswire (Mon, 2-Mar 5:31 PM ET)
Market Chameleon (Fri, 27-Feb 6:52 AM ET)
Globe Newswire (Thu, 26-Feb 4:05 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Globe Newswire (Mon, 23-Feb 4:05 PM ET)
Relay Therapeutics Sets Financial Results Date as Phase 3 Trials on Zovegalisib Progress
Market Chameleon (Fri, 20-Feb 3:40 AM ET)
Globe Newswire (Thu, 19-Feb 5:55 PM ET)
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Wed, 4-Feb 4:05 PM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of March 26, 2026, RLAY stock price climbed to $10.12 with 3,871,226 million shares trading.
RLAY has a beta of 2.01, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.23 to the broad based SPY ETF.
RLAY has a market cap of $1.75 billion. This is considered a Small Cap stock.
Last quarter Relay Therapeutics reported $7 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.07.
In the last 3 years, RLAY traded as high as $19.23 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
RLAY has outperformed the market in the last year with a return of +241.9%, while the SPY ETF gained +13.4%. In the last 3 month period, RLAY beat the market returning +17.0%, while SPY returned -6.3%. However, in the most recent 2 weeks RLAY has underperformed the stock market by returning -6.3%, while SPY returned -4.4%.
RLAY support price is $9.17 and resistance is $10.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
